Investment ThemesDetailed Quotes
Gene Editing
Watchlist
Gene Editing is the ability to make highly specific changes in the DNA sequence of a living organism, essentially customizing its genetic makeup. It demonstrates great potential in gene research, gene therapy and genetic improvement. The Gene Editing concept includes major US-listed companies whose businesses are involved in gene editing.
- 1389.037
- -24.179-1.71%
Close Mar 31 16:00 ET
1397.421High1355.479Low
1393.634Open1413.215Pre Close43.61MVolume2RiseLossP/E (Static)1.69BTurnover--Flatline3.39%Turnover Ratio166.57BMarket Cap8Fall164.80BFloat Cap
Constituent Stocks: 10Top Rising: BLUE+19.61%
Strong buyer 🚀🚀🤑🤑
🚀😉
good earning recently with a little bump 👀
SOMERVILLE, Mass.—(BUSINESS WIRE)—March 28, 2025— bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird”) today confirmed it has received an unsolicited non-binding written proposal (the “Ayrmid Proposal”) from Ayrmid Ltd (“Ayrmid”) to acquire bluebird for an upfront cash payment of $4.50 per share and a one-time contingent value right...
Bluebird Gets New M&A Bid, Seeking To Top Private Equity Offer' - Endpoints News
Beam Therapeutics Announces Clearance of Investigational New Drug Application for Beam-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (Aatd) by the United States (U.S.) Food and Drug Administration
No comment yet